Erasca (ERAS) Competitors $2.59 -0.05 (-1.89%) (As of 10:02 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ERAS vs. RLAY, NUVB, BCYC, VERV, LYEL, MOR, VCEL, KYMR, SWTX, and GMTXShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Relay Therapeutics (RLAY), Nuvation Bio (NUVB), Bicycle Therapeutics (BCYC), Verve Therapeutics (VERV), Lyell Immunopharma (LYEL), MorphoSys (MOR), Vericel (VCEL), Kymera Therapeutics (KYMR), SpringWorks Therapeutics (SWTX), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Relay Therapeutics Nuvation Bio Bicycle Therapeutics Verve Therapeutics Lyell Immunopharma MorphoSys Vericel Kymera Therapeutics SpringWorks Therapeutics Gemini Therapeutics Relay Therapeutics (NASDAQ:RLAY) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation. Is RLAY or ERAS more profitable? Erasca's return on equity of -42.26% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -45.75% -40.75% Erasca N/A -42.26%-34.97% Which has higher valuation and earnings, RLAY or ERAS? Erasca has lower revenue, but higher earnings than Relay Therapeutics. Erasca is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$25.55M29.94-$341.97M-$2.61-1.75ErascaN/AN/A-$125.04M-$0.83-3.12 Which has more risk & volatility, RLAY or ERAS? Relay Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Do analysts prefer RLAY or ERAS? Relay Therapeutics currently has a consensus price target of $21.22, suggesting a potential upside of 364.38%. Erasca has a consensus price target of $6.08, suggesting a potential upside of 134.88%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Relay Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Erasca 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do institutionals and insiders hold more shares of RLAY or ERAS? 97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by insiders. Comparatively, 21.5% of Erasca shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to RLAY or ERAS? In the previous week, Erasca had 12 more articles in the media than Relay Therapeutics. MarketBeat recorded 15 mentions for Erasca and 3 mentions for Relay Therapeutics. Erasca's average media sentiment score of 0.80 beat Relay Therapeutics' score of 0.60 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer RLAY or ERAS? Relay Therapeutics received 31 more outperform votes than Erasca when rated by MarketBeat users. However, 70.59% of users gave Erasca an outperform vote while only 67.90% of users gave Relay Therapeutics an outperform vote. CompanyUnderperformOutperformRelay TherapeuticsOutperform Votes5567.90% Underperform Votes2632.10% ErascaOutperform Votes2470.59% Underperform Votes1029.41% SummaryRelay Therapeutics and Erasca tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$732.27M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-3.124.9789.5613.60Price / SalesN/A371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book1.6310.306.976.33Net Income-$125.04M$153.61M$119.04M$225.93M7 Day Performance-7.83%-1.73%-1.78%-0.96%1 Month Performance-5.13%-7.26%-3.59%1.06%1 Year Performance18.81%31.10%31.64%26.59% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca2.8027 of 5 stars$2.59-1.9%$6.08+134.9%+17.3%$732.27MN/A-3.12126Analyst ForecastAnalyst RevisionRLAYRelay Therapeutics3.2712 of 5 stars$4.57-1.9%$21.22+364.4%-44.5%$764.93M$25.55M0.00304Gap DownNUVBNuvation Bio2.7307 of 5 stars$2.57-0.4%$6.60+156.8%+91.5%$864.99MN/A0.0060BCYCBicycle Therapeutics2.8475 of 5 stars$20.10-1.3%$40.13+99.6%+49.4%$955.76M$26.98M0.00240Analyst RevisionVERVVerve Therapeutics2.4352 of 5 stars$4.54-0.2%$25.75+467.2%-63.2%$384.36M$11.76M0.00110LYELLyell Immunopharma0.4947 of 5 stars$1.02-1.0%$1.00-2.0%-46.9%$284.80M$130,000.00-1.30270MORMorphoSys0.1344 of 5 stars$18.96flat$10.48-44.8%N/A$2.86B$238.28M-5.45730VCELVericel1.0997 of 5 stars$57.63+0.6%$58.14+0.9%+56.1%$2.84B$197.52M954.49300Analyst ForecastKYMRKymera Therapeutics1.4071 of 5 stars$43.71-0.8%$52.13+19.3%+110.9%$2.83B$78.59M0.00170Analyst ForecastSWTXSpringWorks Therapeutics2.0472 of 5 stars$37.20-0.6%$67.00+80.1%+68.5%$2.77B$5.45M0.00305Analyst ForecastGMTXGemini TherapeuticsN/A$62.55+5.0%N/A+14.7%$2.71BN/A-62.5530 Related Companies and Tools Related Companies Relay Therapeutics Alternatives Nuvation Bio Alternatives Bicycle Therapeutics Alternatives Verve Therapeutics Alternatives Lyell Immunopharma Alternatives MorphoSys Alternatives Vericel Alternatives Kymera Therapeutics Alternatives SpringWorks Therapeutics Alternatives Gemini Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ERAS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
